Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437840 | 0.98 | EPHX1 (0.74) | EPHX1HPGDMAPK1EPHX2KMT2A | |
| Bicarbonate SCHEMBL9234681 | 0.97 | EPHX1 (0.72) | EPHX1HPGDMAPK1EPHX2KMT2A | |
| SCHEMBL2166701 | 0.94 | EPHX1 (0.68) | EPHX1HPGDMAPK1EPHX2KMT2A | |
| SCHEMBL26131308 | 0.93 | EPHX1 (0.74) | EPHX1HPGDMAPK1EPHX2RAB9A | |
| SCHEMBL1514783 | 0.92 | EPHX1 (0.64) | EPHX1HPGDMAPK1EPHX2KMT2A | |
| SCHEMBL1609547 | 0.88 | EPHX1 (0.59) | EPHX1HPGDMAPK1EPHX2KMT2A | |
| SCHEMBL3771276 | 0.88 | EPHX1 (0.59) | EPHX1HPGDMAPK1EPHX2KMT2A | |
| SCHEMBL609758 | 0.87 | EPHX1 (0.63) | EPHX1HPGDMAPK1EPHX2KMT2A | |
| SCHEMBL29979852 | 0.87 | EPHX1 (0.63) | EPHX1HPGDMAPK1EPHX2KMT2A | |
| SCHEMBL5142050 | 0.87 | EPHX1 (1.00) | EPHX1HPGDEPHX2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1616859-B1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | claimed |
| US-12528792-B2 | Sulfonamide compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2026-01-20 | — | — | US | disclosed |
| US-20240317717-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2024-09-26 | — | — | US | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| EP-4249475-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2023-09-27 | — | — | EP | disclosed |
| CN-116438167-A | Compounds having O-GlcNAc enzyme inhibitory activity and uses thereof | 美迪福伦DBT有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4028395-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022108377-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF | (주) 메디프론디비티 | 2022-05-27 | — | — | WO | disclosed |
| WO-2021072487-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317717-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | STS, TP53, SQOR | EPHX1 2647/4885HPGD 2045/4885MAPK1 4215/4885 |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | OGA, OGT, ENGASE | EPHX1 1099/4885HPGD 3738/4885MAPK1 3361/4885 |
| US-12528792-B2 | Sulfonamide compounds and the use thereof in the treatment of cancer | SLC10A6, SLCO4C1, SLCO2A1 | EPHX1 980/4885HPGD 2378/4885MAPK1 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.